HIV

Long-term infections with other pathogens have been suspected as the cause of mental impairment in patients with HIV. However, new research suggests that this might not be the case.

To curb an estimated 6% to 11% increase in Medicare Part D spending, 3 states have already placed limitations on which patients with chronic hepatitis C are candidates for treatment with novel antiviral agents.

Pharmacists can substantially lower risk for cardiovascular disease.

Patients with bipolar disorder and other mental illnesses are more likely to be tested for human immunodeficiency virus.

The role of pharmacists in HIV care across ambulatory care settings is expanding.

According to a new study, a CCR5-blocking drug used to treat HIV may also be able to slow prostate cancer metastasis.

Tablets treat HIV-1 infection in combination with other antiretroviral agents for pediatric patients.

Study suggests that HIV adaptations are evolving it into a weaker virus.

The FDA granted a tentative approval for 2 dosages of abacavir/lamivudine tablets for oral suspension to treat HIV-1 infection in pediatric patients, according to a Mylan, Inc, press release.

Mylan, Inc, announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc, under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide as both a single agent product and in combination with other drugs.

Study finds that HIV drug regimens that exclude efavirenz are as effective as first-line antiretroviral treatment.

Beginning therapy within 12 months of HIV detection associated with lower AIDS risk.

Of the 1.2 million Americans with human immunodeficiency virus in 2011, 70% did not have their condition under control.

Study finds treatment that prevents transmission of virus from mother to child leads to reduced heart performance.

Three-drug regimen will lead to new treatment protocols for transplant patients, study finds.

A study from Merck has demonstrated high response to grazoprevir/elbasvir with and without ribavirin across various hepatitis C virus populations, including difficult-to-cure patients.

A trio of studies from AbbVie provides good news for patients with hepatitis C virus, including those with comorbid HIV or cirrhosis.

Women may need more frequent ART doses to prevent HIV transmission than men, a mathematical model suggests

If approved, it would be Gilead's first single-tablet HIV regimen to contain TAF.

Gilead Sciences, Inc., has submitted a new drug application to the FDA for its investigational single-tablet regimen for HIV infection in adult patients.

Following completion of phase 2 trial, phase 3 enrollment expected to start by end of the year.

An investigational HIV drug developed by Merck exhibited a strong overall safety and efficacy profile in a recently completed phase 2b study.

Discovery offers potential target for future HIV treatments.

Could the key to fighting modern illnesses lie in a disease that was an epidemic centuries ago?

Researchers identify mechanisms that trigger hematopoietic stem cell production.